Riskpilot← Back to searchSign inGet full accessVigmed AB
ABActiveOrg 5567808018Kungsgatan 6Research and experimental development on natural sciences and engineering · NACE 7210Est. 20097 employees
Revenue 2024
SEK 16,8M
+10% vs 2023
EBITDA margin
-7.6%
+73% vs 2023
Equity ratio
36.3%
Financial strength
Net profit 2024
SEK -1,2M
+76% vs 2023
| Revenue | SEK 16,8M | +10% |
| EBITDA | SEK -1,3M | +73% |
| Net profit | SEK -1,2M | +76% |
| Total assets | SEK 13M | -6% |
| Equity | SEK 4,7M | -20% |
| Employees | 7 | — |
Legal name
Vigmed AB
Org number
5567808018
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
14 april 2009
Share capital
SEK 905 000
Employees
7 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall driva utveckling och innovationer kring medicinsk teknik samt tillverkning och försäljning av sådan och därmed förenlig verksamhet.
Address
Kungsgatan 6
Phone
+4642280090
Email
info@vigmed.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 13 110 | 22 444 | 9 171 | 36 332 | 13 454 | 15 300 | 16 809 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −41 406 | −29 876 | −20 570 | −14 401 | −17 330 | −23 608 | −4 113 | −9 022 | −4 817 | −1 283 |
| Depreciation & amort. | −5 682 | −8 118 | −6 311 | −9 536 | −9 028 | −21 356 | −1 128 | −0 | −0 | −2 |
| EBIT | −47 088 | −37 994 | −26 881 | −23 937 | −26 358 | −44 964 | −5 241 | −9 022 | −4 817 | −1 285 |
| Net financials | −432 | −309 | −502 | −2 983 | −1 250 | 1 093 | −1 920 | 382 | −375 | −91 |
| Profit before tax | −47 521 | −38 304 | −27 383 | −26 920 | −27 608 | −43 871 | −6 725 | −7 756 | −4 979 | −1 197 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −47 521 | −38 304 | −27 383 | −26 920 | −27 608 | −43 871 | −6 725 | −7 756 | −4 979 | −1 197 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 35 652 | 38 922 | 63 255 | 47 029 | 51 390 | 58 689 | 50 458 | 19 194 | 13 886 | 13 042 |
| Equity | 1 404 | 2 600 | 3 217 | 897 | 1 789 | 7 284 | 18 663 | 10 906 | 5 927 | 4 730 |
| Long-term debt | 18 500 | 19 000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23 |
| Short-term debt | 15 748 | 17 322 | 60 038 | 46 132 | 49 601 | 51 405 | 31 796 | 8 287 | 7 959 | 8 289 |
| Total debt | 34 248 | 36 322 | 60 038 | 46 132 | 49 601 | 51 405 | 31 796 | 8 287 | 7 959 | 8 312 |
EBITDA margin
-7.6%
This company
15.8%
Market median
-148% vs market
20152024
Equity ratio
36.3%
This company
38.2%
Market median
+5% vs market
20152024
Return on equity
-25.3%
This company
18.4%
Market median
-238% vs market
20152024
Net profit margin
-7.1%
This company
8.1%
Market median
-188% vs market
20152024
Asset turnover
1.29×
This company
1.12×
Market median
+15% vs market
20152024
Debt / equity
1.76×
This company
0.62×
Market median
-184% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HO Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
DA Chief Auditor | Chief Auditor | 2022 | — | — |
AI Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
JF Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2024 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Vigmed AB (this company)
Vigmed Asia LimitedVigmed Medical Device Co (Beijing)Board members of Vigmed AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Henrik Olsen | Chief Executive Officer | 0 companies |
| Dan Andreas Johansson | Chief Auditor | 0 companies |
| Anna Ingrid Elisabeth Andersson | Chief Executive Officer | 0 companies |
| Johan Fredrik Thörne | Chief Executive Officer | 0 companies |
| Stefan Walter Richard Dr. Gebauer | Deputy Board Member | 0 companies |
| Thomas Karl Scheurecker | Board of Directors | 0 companies |
| Rainer Helmut Perneker | Board of Directors | 0 companies |
| Georg Heftberger | Deputy Board Member | 0 companies |